Opsonising Antibodies to P. falciparum Merozoites Associated with Immunity to Clinical Malaria

Naturally acquired humoral immunity to the malarial parasite Plasmodium falciparum can protect against disease, although the precise mechanisms remain unclear. Although antibody levels can be measured by ELISA, few studies have investigated functional antibody assays in relation to clinical outcomes. In this study we applied a recently developed functional assay of antibody-mediated opsonisation of merozoites, to plasma samples from a longitudinal cohort study conducted in a malaria endemic region of Papua New Guinea (PNG). Phagocytic activity was quantified by flow cytometry using a standardized and high-throughput protocol, and was subsequently evaluated for association with protection from clinical malaria and high-density parasitemia. Opsonising antibody responses were found to: i) increase with age, ii) be enhanced by concurrent infection, and iii) correlate with protection from clinical episodes and high-density parasitemia. Stronger protective associations were observed in individuals with no detectable parasitemia at baseline. This study presents the first evidence for merozoite phagocytosis as a correlate of acquired immunity and clinical protection against P. falciparum malaria.

[1]  Danny W. Wilson,et al.  Efficient Measurement of Opsonising Antibodies to Plasmodium falciparum Merozoites , 2012, PloS one.

[2]  Danny W. Wilson,et al.  The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria , 2012, PloS one.

[3]  J. Simpson,et al.  New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women , 2012, The Journal of infectious diseases.

[4]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[5]  C. Rogier,et al.  Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. , 2011, The Lancet. Infectious diseases.

[6]  Danny W. Wilson,et al.  Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans , 2011, PloS one.

[7]  S. Cousens,et al.  Protection against malaria by MSP3 candidate vaccine. , 2011, The New England journal of medicine.

[8]  R. Noor,et al.  A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children , 2011, PloS one.

[9]  G. Alter,et al.  Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. , 2011, Virology.

[10]  Olivier Restif,et al.  Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells , 2011, Immunology.

[11]  Prashant Yadav,et al.  A Research Agenda for Malaria Eradication: Vaccines , 2019 .

[12]  T. Triglia,et al.  Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against Plasmodium falciparum Malaria , 2010, The Journal of Immunology.

[13]  A. Cowman,et al.  Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Danny W. Wilson,et al.  Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development , 2010, Proceedings of the National Academy of Sciences.

[15]  L. Marrama,et al.  Clinical Protection from Falciparum Malaria Correlates with Neutrophil Respiratory Bursts Induced by Merozoites Opsonized with Human Serum Antibodies , 2010, PloS one.

[16]  Jack S. Richards,et al.  The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.

[17]  M. D'Ombrain,et al.  Cellular Tumor Necrosis Factor, Gamma Interferon, and Interleukin-6 Responses as Correlates of Immunity and Risk of Clinical Plasmodium falciparum Malaria in Children from Papua New Guinea , 2009, Infection and Immunity.

[18]  P. Gilson,et al.  Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness , 2009, Infection and Immunity.

[19]  M. D'Ombrain,et al.  Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  G. Belz,et al.  Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8α+ dendritic cells , 2008, Proceedings of the National Academy of Sciences.

[21]  R. Chilengi,et al.  Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children , 2008, Malaria Journal.

[22]  O. Gaye,et al.  Long-term asymptomatic carriage of Plasmodium falciparum protects from malaria attacks: a prospective study among Senegalese children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Conway,et al.  Duration of Naturally Acquired Antibody Responses to Blood-Stage Plasmodium falciparum Is Age Dependent and Antigen Specific , 2008, Infection and Immunity.

[24]  Andrea Crisanti,et al.  Profiling the antibody immune response against blood stage malaria vaccine candidates. , 2007, Clinical chemistry.

[25]  M. D'Ombrain,et al.  γδ‐T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN‐γ response to Plasmodium falciparum malaria , 2007 .

[26]  D. Conway,et al.  IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life , 2007, Malaria Journal.

[27]  I. Mueller,et al.  The risk of malarial infections and disease in Papua New Guinean children. , 2007, The American journal of tropical medicine and hygiene.

[28]  A. Holder,et al.  The Importance of Human FcγRI in Mediating Protection to Malaria , 2007, PLoS pathogens.

[29]  M. Dziegiel,et al.  A Novel Antibody-Dependent Cellular Cytotoxicity Mechanism Involved in Defense against Malaria Requires Costimulation of Monocytes FcγRII and FcγRIII1 , 2007, The Journal of Immunology.

[30]  D. Conway,et al.  High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. , 2006, Vaccine.

[31]  P. Zimmerman,et al.  Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. , 2006, The American journal of tropical medicine and hygiene.

[32]  K. Marsh,et al.  Immune effector mechanisms in malaria , 2006, Parasite immunology.

[33]  P. Kremsner,et al.  Fcγ receptor‐mediated phagocytosis of Plasmodium falciparum‐infected erythrocytes in vitro , 2002, Clinical and experimental immunology.

[34]  Thomas A. Smith,et al.  A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.

[35]  B. Lell,et al.  Malarial anaemia in African children associated with high oxygen-radical production , 2000, The Lancet.

[36]  A. Thomas,et al.  The Glutamate-Rich Protein (GLURP) of Plasmodium falciparum Is a Target for Antibody-Dependent Monocyte-Mediated Inhibition of Parasite Growth In Vitro , 1998, Infection and Immunity.

[37]  D. Stüber,et al.  Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers. , 1992, Journal of immunology.

[38]  A. Sabchareon,et al.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes , 1990, The Journal of experimental medicine.

[39]  K. Mendis,et al.  Human immune responses against sexual stages of malaria parasites: considerations for malaria vaccines. , 1990, International journal for parasitology.

[40]  B. Descamps-Latscha,et al.  Activation of phagocyte oxidative metabolism by opsonized Plasmodium falciparum merozoites. , 1990, Acta tropica.

[41]  S. Khusmith,et al.  Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status , 1987, Infection and immunity.

[42]  A. Saul.  Kinetic constraints on the development of a malaria vaccine , 1987, Parasite immunology.

[43]  S. Khusmith,et al.  Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals , 1982, Infection and immunity.

[44]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[45]  M. Dziegiel,et al.  A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. , 2007, Journal of immunology.

[46]  D. Hansen,et al.  Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. , 2004, International journal for parasitology.

[47]  A. Tartar,et al.  Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. , 1994, Blood.

[48]  I. McGregor.  THE PASSIVE TRANSFER OF HUMAN MALARIAL IMMUNITY. , 1964, The American journal of tropical medicine and hygiene.